While there has been a study looking at crizotinib versus chemotherapy in anaplastic lymphoma kinase (ALK) positive NSCLC [1], there is no prospective clinical evidence that indicates the efficacy of ALK TKIs for ALK positive patients with poor PS. Here, ALK is linked to non-small cell lung carcinoma.